Greenbrook TMS Announces Dates for Its Fourth Quarter and Year End 2022 Financial Results
FOURTH QUARTER AND YEAR END 2022 CONFERENCE CALL DETAILS:
Dial in Numbers:
Webcast:
For more information or to listen to the call via webcast, please visit:
www.greenbrooktms.com/investors/events.htm
For those that plan on accessing the conference call or webcast, please allow ample time prior to the call time.
Conference Call Replay:
Following the live call, a replay will be available on the Investor Relations section of the Company’s website, www.greenbrooktms.com/investors/events.htm
About
Operating through 133 Company-operated treatment centers (following completion of the Company's previously-announced restructuring plan), Greenbrook is a leading provider of Transcranial Magnetic Stimulation ("TMS") and Spravato® (esketamine nasal spray), FDA-cleared, non-invasive therapies for the treatment of Major Depressive Disorder ("MDD") and other mental health disorders, in
View source version on businesswire.com: https://www.businesswire.com/news/home/20230414005425/en/
For further information please contact:
Investor Relations
Contact Information:
investorrelations@greenbrooktms.com
1-855-797-4867
Source: